Rinne J O, Laihinen A, Någren K, Ruottinen H, Ruotsalainen U, Rinne U K
Department of Neurology, Turku University Cyclotron-PET Center, University of Turku, Finland.
Synapse. 1995 Oct;21(2):97-103. doi: 10.1002/syn.890210202.
The monoamine transporter was studied in 4 healthy controls and 5 patients with early Parkinson's disease (PD), who had not received any antiparkinsonian medication, by means of positron emission tomography (PET) using two novel ligands, [11C]beta-CIT and [11C]beta-CFT. Both ligands showed highest uptake in the striatum. There was intermediate accumulation of activity in the thalamus and midbrain, which was more marked for [11C]beta-CIT than for [11C]beta-CFT. In the cortical areas, uptake of both ligands was not different from that seen in the cerebellum. In the controls, the putamen-to-cerebellum and caudate-to-cerebellum ratios for [11C]beta-CFT were higher than those for [11C]beta-CIT (putamen: 3.15 +/- 0.39 for [11C]beta-CFT, and 1.84 +/- 0.10 for [11C]beta-CIT; caudate: 3.15 +/- 0.31 for [11C]beta-CFT, and 1.95 +/- 0.17 for [11C]beta-CIT). Reduction from mean control value in PD patients was greater for [11C]beta-CFT (45% in the putamen contralateral to the predominant symptoms, P < 0.001) than for [11C]beta-CIT (20%, P > 0.05). [11C]beta-CFT uptake in the caudate nucleus was also diminished in PD patients (to 80% of the control mean, P < 0.05), whereas [11C]beta-CIT was within normal range (reduced to 90% of the control mean). These results indicate that both [11C]beta-CIT and [11C]beta-CFT are useful PET ligands to study brain monoamine transporter in healthy controls and in patients with PD. However, [11C]beta-CFT seems superior to [11C]beta-CIT in this respect.
通过正电子发射断层扫描（PET），使用两种新型配体[11C]β-CIT和[11C]β-CFT，对4名健康对照者和5名未接受过任何抗帕金森病药物治疗的早期帕金森病（PD）患者的单胺转运体进行了研究。两种配体在纹状体中的摄取量均最高。丘脑和中脑有中等程度的活性积聚，[11C]β-CIT比[11C]β-CFT更明显。在皮质区域，两种配体的摄取与小脑所见无差异。在对照者中，[11C]β-CFT的壳核与小脑以及尾状核与小脑的比值高于[11C]β-CIT（壳核：[11C]β-CFT为3.15±0.39，[11C]β-CIT为1.84±0.10；尾状核：[11C]β-CFT为3.15±0.31，[11C]β-CIT为1.95±0.17）。PD患者中，[11C]β-CFT从对照者平均值的降低幅度（主要症状对侧壳核降低45%，P<0.001）大于[11C]β-CIT（降低20%，P>0.05）。PD患者尾状核中[11C]β-CFT的摄取也减少（降至对照者平均值的80%，P<0.05），而[11C]β-CIT在正常范围内（降至对照者平均值的90%）。这些结果表明，[11C]β-CIT和[11C]β-CFT都是研究健康对照者和PD患者脑单胺转运体的有用PET配体。然而，在这方面[11C]β-CFT似乎优于[11C]β-CIT。
